L.K. Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 05-01-2025
- Paid Up Capital ₹ 0.97 M
as on 05-01-2025
- Company Age 31 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.40 M
as on 05-01-2025
- Revenue 17.71%
(FY 2022)
- Profit -82.20%
(FY 2022)
- Ebitda -36.86%
(FY 2022)
- Net Worth 1.54%
(FY 2022)
- Total Assets 0.26%
(FY 2022)
About L.K. Pharmaceuticals
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.97 M.
The company currently has active open charges totaling ₹0.40 M.
Naga Lingamallu, Vijaya Lingamallu, Krishnamurty Lingamallu, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230AP1993PTC015771
- Company No.
015771
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 May 1993
- Date of AGM
26 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Godavari, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at L.K. Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naga Lingamallu  | Managing Director | 17-May-1993 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Krishnamurty Lingamallu | Director | 19-Nov-2007 | Current |
| Vijaya Lingamallu | Director | 17-May-1993 | Current |
| Ramadevi Kolisetty | Director | 31-Mar-2021 | Current |
Financial Performance of L.K. Pharmaceuticals.
L.K. Pharmaceuticals Pvt. Ltd., for the financial year ended 2022, experienced significant growth in revenue, with a 17.71% increase. The company also saw a substantial fall in profitability, with a 82.2% decrease in profit. The company's net worth moved up by a moderate rise of 1.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of L.K. Pharmaceuticals?
In 2015, L.K. Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Vysya Bank Ltd. Creation Date: 26 Feb 1998 | ₹0.20 M | Open |
The Vysya Bank Ltd. Creation Date: 06 May 1994 | ₹0.20 M | Open |
How Many Employees Work at L.K. Pharmaceuticals?
Unlock and access historical data on people associated with L.K. Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of L.K. Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped L.K. Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
